Haemonetics Corporation - Asset Resilience Ratio
Haemonetics Corporation (HAE) has an Asset Resilience Ratio of 14.59% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See HAE working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (1997–2025)
This chart shows how Haemonetics Corporation's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Haemonetics Corporation balance sheet assets.
Liquid Assets Composition Over Time
This chart breaks down Haemonetics Corporation's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read HAE total debt and obligations for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $363.37 Million | 14.59% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $363.37 Million | 14.59% |
Asset Resilience Insights
- Moderate Liquidity: Haemonetics Corporation has 14.59% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Haemonetics Corporation Industry Peers by Asset Resilience Ratio
Compare Haemonetics Corporation's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
TransMedics Group Inc
NASDAQ:TMDX |
Medical Devices | 0.00% |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223 |
Medical Devices | 0.84% |
|
Novocure Ltd
NASDAQ:NVCR |
Medical Devices | 43.72% |
|
Shenzhen New Industries Biomedical
SHE:300832 |
Medical Devices | 9.95% |
|
Jafron Biomedical Co Ltd
SHE:300529 |
Medical Devices | 34.37% |
|
Hangzhou AGS MedTech Co. Ltd. A
SHG:688581 |
Medical Devices | 18.80% |
|
Nanjing Vishee Medical Technology Co Ltd
SHG:688580 |
Medical Devices | 10.74% |
|
Nanjing Medlander Medical Technology Co. Ltd. A
SHG:688273 |
Medical Devices | 34.29% |
Annual Asset Resilience Ratio for Haemonetics Corporation (1997–2025)
The table below shows the annual Asset Resilience Ratio data for Haemonetics Corporation.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-03-31 | 12.52% | $306.76 Million | $2.45 Billion | +4.30pp |
| 2024-03-31 | 8.22% | $180.47 Million | $2.20 Billion | -6.54pp |
| 2023-03-31 | 14.76% | $285.58 Million | $1.93 Billion | +0.81pp |
| 2022-03-31 | 13.95% | $259.50 Million | $1.86 Billion | +3.39pp |
| 2021-03-31 | 10.57% | $192.31 Million | $1.82 Billion | -0.27pp |
| 2020-03-31 | 10.84% | $137.31 Million | $1.27 Billion | -2.45pp |
| 2019-03-31 | 13.28% | $169.35 Million | $1.27 Billion | -1.28pp |
| 2018-03-31 | 14.56% | $180.17 Million | $1.24 Billion | +3.29pp |
| 2017-03-31 | 11.27% | $139.63 Million | $1.24 Billion | -- |
| 2016-03-31 | 0.00% | $0.00 | $1.32 Billion | -- |
| 2015-03-31 | 0.00% | $0.00 | $1.48 Billion | -- |
| 2014-03-31 | 0.08% | $1.25 Million | $1.52 Billion | -- |
| 2013-03-31 | 0.00% | $0.00 | $1.46 Billion | -- |
| 2012-03-31 | 0.00% | $0.00 | $910.63 Million | -- |
| 2011-03-31 | 0.00% | $0.00 | $833.26 Million | -- |
| 2004-03-31 | 0.47% | $1.90 Million | $407.39 Million | -0.29pp |
| 2003-03-31 | 0.75% | $2.70 Million | $359.21 Million | -8.19pp |
| 2002-03-31 | 8.94% | $32.64 Million | $364.92 Million | -0.63pp |
| 2001-03-31 | 9.57% | $33.04 Million | $345.31 Million | +7.28pp |
| 2000-03-31 | 2.29% | $8.00 Million | $349.11 Million | -1.16pp |
| 1999-03-31 | 3.45% | $12.30 Million | $356.40 Million | -0.08pp |
| 1998-03-31 | 3.53% | $11.90 Million | $336.70 Million | -0.67pp |
| 1997-03-31 | 4.20% | $13.60 Million | $323.50 Million | -- |
About Haemonetics Corporation
Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information tech… Read more